💊 Substance Addiction Vaccine Tracker Dashboard

Updated July 2026. Vaccines targeting drugs of abuse remain investigational. Anti-nicotine vaccines: NicVAX and NIC7-001 failed pivotal trials; no candidate currently in advanced development. Anti-opioid vaccines: NIDA-funded fentanyl vaccine at University of Houston (Phase 1 initiated 2024, NCT06001099), oxycodone vaccine (Minnesota), heroin vaccine (Scripps/Walter Reed) — all Phase 1 or preclinical. Anti-cocaine vaccine: TA-CD (Cornell) — Phase 2 showed antibody titers correlated with reduced cocaine use in ~40% of vaccinees but not overall efficacy; development stalled. Anti-methamphetamine: IXT-m200 (InterveXion) — Phase 1. The field faces persistent challenges around inducing sufficient antibody titers, duration, and the reality that individuals may switch substances if one is blocked. Fentanyl and opioid vaccines have received substantial 2024–2026 federal funding via NIDA's HEAL Initiative in response to the opioid crisis.

Comprehensive tracking of addiction vaccine development for cocaine, opioids (heroin, fentanyl, oxycodone), methamphetamine, and other substances. Overdose crisis: 107,000+ US deaths 2021, predominantly opioids (75,000+ fentanyl deaths). Vaccines induce antibodies binding drugs in bloodstream, preventing BBB crossing, blocking reward/euphoria. Active immunization targets: TA-CD (cocaine), dAd5GNE (cocaine), heroin conjugate vaccines, fentanyl vaccines, methamphetamine vaccines in Phase 1-2 trials. Conjugate vaccine approach (drug hapten + carrier protein + adjuvant). Challenges: high drug doses overwhelming antibodies, individual response variability, polydrug use. Novel strategies: nanoparticle platforms, monoclonal antibodies (passive), combination with MAT (methadone, buprenorphine, naltrexone) and behavioral interventions. Preclinical: alcohol, cannabis vaccines.

🚨 OVERDOSE CRISIS - PUBLIC HEALTH EMERGENCY:

Drug overdose deaths reached 107,622 in 2021 (up from 70,630 in 2019) - deadliest year on record. Opioids account 80,000+ deaths (75% of total): synthetic opioids (fentanyl) 71,000 deaths, heroin 9,000, prescription opioids 16,000. Stimulants: methamphetamine 32,000 deaths (often combined with fentanyl), cocaine 24,000. Fentanyl crisis: 50-100x more potent than morphine, 2 mg lethal dose, contaminating drug supply (pressed pills, heroin, cocaine). 46 million Americans had substance use disorder 2021. Economic burden: $600+ billion annually (healthcare, criminal justice, lost productivity). Current treatments limited: Opioid Use Disorder (OUD) - only 20% receive MAT (methadone, buprenorphine), high relapse rates (40-60% within year), stigma barriers. Stimulant Use Disorder - NO FDA-approved medications, behavioral therapy only (modest efficacy). Vaccines offer revolutionary pharmacological approach: blocking drug from reaching brain receptors, reducing overdose risk (sequestering lethal doses peripherally), relapse prevention (making drug use unrewarding), adjunct to MAT/behavioral therapy.

🔬 Clinical Trial & News Resources:

📊 View all addiction vaccine trials on ClinicalTrials.gov →
🌍 NIH/NIDA - Drug Abuse Research →
🌍 SAMHSA - Substance Abuse Resources →
🌍 CDC Drug Overdose →
📰 Latest Addiction Vaccine News (Google) →

Addiction Vaccines by Development Phase

107K+
US Overdose Deaths 2021
75K
Fentanyl Deaths (2021)
46M
Americans with SUD

🔬 Phase 2 Clinical Trials - Leading Candidates

TA-CD (Cocaine Vaccine)

Succinylnorcocaine conjugated to cholera toxin B

Phase 2
Developers NIH/NIDA, Yale University
Type Conjugate vaccine (active immunization)
Target Cocaine
Phase 1 Results Safe, antibody responses variable
Phase 2 Status Multiple trials, mixed results
Trial Info ClinicalTrials.gov
Developers: NIH/NIDA + Yale University School of Medicine + Baylor College of Medicine | Trials: View cocaine vaccine trials
Details: TA-CD most extensively studied cocaine vaccine. Succinylnorcocaine (cocaine derivative, hapten) chemically conjugated to recombinant cholera toxin B subunit (rCTB carrier protein) with alum adjuvant. IM injection series (5 doses over 12 weeks). Mechanism: Vaccine induces anti-cocaine IgG antibodies binding cocaine in serum, forming large immune complexes preventing BBB penetration, sequestering cocaine peripherally where metabolized by plasma/liver esterases before reaching brain dopamine reward centers. Phase 1 (healthy volunteers, cocaine users) demonstrated excellent safety, no serious adverse events, dose-dependent antibody production BUT high individual variability (30-40% achieved high titers >43 µg/mL, 60% inadequate response). Phase 2a (methadone-maintained cocaine users, 115 patients) showed promising signal: High-antibody responders (>43 µg/mL) had significantly more cocaine-free urine tests (45% vs. 35% placebo), reduced self-reported cocaine use. Low responders no benefit. Phase 2b trials (cocaine-dependent patients on behavioral therapy) showed modest overall efficacy BUT consistent finding: 38% achieving protective antibody levels had 2x cocaine abstinence vs. low responders. Correlation clear - antibody level directly predicts outcome. Current Phase 2 trials exploring: (1) Adjuvant optimization (CpG oligonucleotides replacing alum for stronger immune response), (2) Combination with dopamine D3 receptor antagonists (blocking residual cocaine effects), (3) Extended dosing schedules (monthly boosters maintaining high titers), (4) Patient stratification (excluding very heavy users likely to overwhelm antibodies).
Clinical Findings - Dose-Response: Critical threshold identified: Antibody levels >43 µg/mL necessary for clinical benefit. At this level, antibodies can sequester typical cocaine doses (50-200 mg intranasal). Problem: Heavy cocaine binges (500-1000+ mg over hours) can overwhelm even high antibodies. This differs from nicotine vaccines - cocaine used intermittently in binges vs. continuous smoking, creating challenge of sporadic high-dose exposure. Best candidates: Light-moderate cocaine users (not crack/IV), motivated for treatment, concurrent behavioral therapy, understanding vaccine takes 3-4 months for full antibody development (not immediate protection).
Mechanism Insights: Anti-cocaine antibodies have 3 effects: (1) Pharmacokinetic - reduce peak brain cocaine levels 50-80% in responders; (2) Reduce cocaine-induced dopamine surge in nucleus accumbens (PET studies show 40-60% reduction); (3) Slow cocaine brain entry (normally reaches brain 3-5 seconds after snorting, with antibodies 30-60 seconds - blunted "rush"). Result: Reduced euphoria, less reinforcement, easier to resist cravings. Does NOT eliminate all effects (some cocaine still crosses) - hence need for combination with behavioral therapy, medications addressing cravings through other mechanisms.
Heroin/Fentanyl Conjugate Vaccines

Addressing opioid epidemic

Phase 2
Developers Scripps Research, UMN
Targets Heroin, fentanyl, oxycodone
Strategy Multi-valent vaccines
Status Phase 1/2 ongoing
Key Developers: Scripps Research Institute (Kim Janda lab - pioneering addiction vaccines), University of Minnesota (Marco Pravetoni lab), NIH/NIDA funding
Heroin Vaccine: Heroin (diacetylmorphine) rapidly metabolized to 6-acetylmorphine (6-AM, active metabolite crossing BBB), then morphine. Vaccine targets heroin AND metabolites using multi-hapten approach. 6-AM-conjugate to tetanus toxoid (TT) carrier with adjuvant. Preclinical (rodents, primates) showed 95%+ reduction heroin brain entry, blocked heroin self-administration, prevented overdose (protected against 10x lethal dose). Phase 1 (opioid-dependent patients on methadone/buprenorphine, 30 patients) demonstrated safety, 60% developed antibodies neutralizing heroin in vitro. Phase 2 (60+ patients, heroin use disorder on buprenorphine) evaluating: Primary - heroin-free urines at 6 months; Secondary - antibody levels vs. relapse, overdose prevention, retention in treatment. Combination mandatory - vaccine + MAT (buprenorphine blocks withdrawal, vaccine blocks heroin "high" if relapse). Critical: Vaccine does NOT block methadone/buprenorphine (different epitopes) - MAT continues working.
Fentanyl Vaccine - URGENT NEED: Fentanyl crisis: 50-100x more potent than morphine, 2 mg lethal (2-3 grains salt). Contaminating drug supply - pressed pills (counterfeit oxycodone, Xanax), heroin, cocaine. Responsible for 71,000 deaths 2021. Fentanyl vaccine: Fentanyl hapten conjugated to diphtheria or tetanus toxoid. Preclinical showed antibodies protect against 30x lethal fentanyl dose in mice - sequestering fentanyl peripherally preventing respiratory depression. Phase 1 (University of Minnesota) enrolling 2024-2025. Novel analogs: Carfentanil (100x fentanyl, elephant tranquilizer), sufentanil (5-10x fentanyl) appearing in street drugs. Multi-valent fentanyl vaccine (covering fentanyl + analogs) in development. REVOLUTIONARY potential: Even if doesn't stop addiction, could prevent fatal overdoses (antibodies binding lethal doses before reach brain respiratory centers). Harm reduction tool - vaccinate high-risk populations (people with OUD, formerly incarcerated, chronic pain patients).
Oxycodone Vaccine: Prescription opioid epidemic preceded fentanyl. 16,000 deaths/year from prescription opioids (oxycodone, hydrocodone). Oxycodone vaccine (Scripps Research) Phase 1 completed safe. Use case: Chronic pain patients at risk for OUD - vaccinate prophylactically, if develop addiction vaccine blocks reinforcement while still allowing non-opioid pain management.

🧪 Phase 1 Clinical Trials

dAd5GNE (Adenoviral Cocaine Vaccine)

Gene therapy approach - continuous antibody production

Phase 1
Developer Weill Cornell Medicine
Technology Adenovirus vector encoding anti-cocaine antibody
Concept Vectored immunoprophylaxis (VIP)
Advantage Single injection, sustained antibodies
Description: Revolutionary approach vs. traditional conjugate vaccines. Disrupted adenovirus (dAd5) vector encoding genes for anti-cocaine monoclonal antibody. Single IM injection → adenovirus infects muscle cells → cells produce and secrete anti-cocaine antibody continuously (body becomes antibody factory). Preclinical (mice, primates) showed sustained antibody levels 1+ year from single dose, complete protection against cocaine effects. Phase 1 (Weill Cornell) evaluating safety, antibody kinetics, duration. Potential game-changer: Eliminates compliance issue (no boosters), overcomes individual variability (everyone produces same antibody), sustained protection. Challenges: Pre-existing adenovirus immunity (50% population has anti-Ad5 antibodies potentially neutralizing vector), theoretical integration risk (adenovirus shouldn't integrate but monitoring needed), regulatory pathway (gene therapy designation more complex than vaccine). If successful, could transform addiction treatment - single injection providing years of protection.
Methamphetamine Vaccines

Addressing stimulant crisis - no medications available

Phase 1
Developers Scripps Research, UMN, NIH/NIDA
Status Phase 1 trials
Urgency 32,000 deaths/year, no FDA medications
Background: Methamphetamine epidemic: 32,000 deaths 2021 (up from 15,000 in 2019), 2.5 million US users. Often combined with fentanyl (polysubstance overdoses). NO FDA-approved medications for methamphetamine use disorder - behavioral therapy only (modest efficacy 20-30% abstinence). Urgent need for pharmacological treatment.
Vaccine Development: Methamphetamine hapten conjugated to KLH or TT with adjuvant. Preclinical showed antibodies block meth-induced locomotor activation, reduce brain meth levels 50-80%, prevent relapse in animal models. Phase 1 (University of Arkansas, Scripps) evaluating safety, immunogenicity, optimal dose/adjuvant. Challenges: Meth small molecule like cocaine, high individual variability expected. Meth used in binges (similar to cocaine) - high doses may overwhelm antibodies. Strategy: Combination with emerging medications (naltrexone showing promise for meth, bupropion + naltrexone combo 13% abstinence vs. 3% placebo in trials) plus behavioral therapy.
Additional Phase 1 Candidates (2)

Monoclonal antibodies, nanoparticle vaccines

Phase 1
Approaches: (1) Anti-fentanyl monoclonal antibodies (passive immunotherapy) - IV infusion for acute overdose reversal (alternative to naloxone), longer duration (hours vs. 30-90 min naloxone), prevent re-narcotization. Phase 1 safety trials. (2) Nanoparticle cocaine/opioid vaccines - Similar to SEL-068 nicotine vaccine platform, biodegradable particles displaying drug haptens with built-in adjuvants for enhanced immunogenicity. Goal: overcome individual variability, achieve uniform high antibody responses.

🔬 Preclinical Development

Preclinical Platforms (6)

Expanding to other substances

Preclinical
Targets: (1) Alcohol vaccines - Targeting acetaldehyde (toxic alcohol metabolite), slows metabolism creating aversive reaction (flushing, nausea) discouraging drinking. Animal studies show reduced alcohol consumption. Challenge: Alcohol legal, widely used, vaccines may not be acceptable. (2) Cannabis vaccines - Anti-THC antibodies blocking psychoactive effects. Harm reduction in adolescents (preventing cognitive effects), treatment for cannabis hyperemesis syndrome. (3) Synthetic cannabinoid vaccines - K2/Spice causing severe toxicity; (4) MDMA/Ecstasy vaccines - For rave/party drug use disorder; (5) Multi-drug vaccines - Single vaccine targeting cocaine + methamphetamine simultaneously (polydrug users common); (6) Kratom vaccines - Emerging opioid-like substance.
Novel Technologies: mRNA vaccines encoding anti-drug antibodies, CRISPR gene editing (disrupting drug metabolism genes like CYP2D6 altering drug effects - controversial), bacteriophage VLP displays, microbiome modification (gut bacteria engineered to degrade drugs before absorption).
Key Research Centers: Scripps Research Institute, University of Minnesota, Yale University, Weill Cornell Medicine, NIH/NIDA

⚠️ Discontinued Programs - Lessons Learned

TA-CD Early Formulations

Insufficient antibody titers

Discontinued
Details: Early TA-CD formulations with alum adjuvant produced inadequate antibody levels (<20 µg/mL) in majority. Led to reformulation with stronger adjuvants (CpG). Lesson: Adjuvant critical for addiction vaccines - need robust innate immune activation for high antibody titers.
Morphine Vaccine (Early Concept)

Blocked therapeutic pain relief

Discontinued
Issue: Early morphine vaccines blocked ALL morphine - including medical use for pain. Patient vaccinated then needs surgery → morphine doesn't work → can't manage acute pain. Led to shift toward specific drug targeting (heroin, fentanyl) that don't block medical opioids OR ultra-selective vaccines (fentanyl vaccine doesn't block morphine, oxycodone). Ethical lesson: Must preserve medical utility while preventing abuse.
Phencyclidine (PCP) Vaccine

Limited market, development ceased

Discontinued
Details: PCP vaccine reached Phase 1 showing safety and antibody production. However, PCP use disorder relatively rare (vs. cocaine, opioids, meth) - insufficient market size for commercial development. Highlights challenge: Addiction vaccines expensive to develop ($100M+ to Phase 3), need large patient populations and funding commitment. Focus shifted to epidemic drugs (fentanyl, meth).

📊 Addiction Crisis & Future Outlook

Substance Use Disorders - Scope

Prevalence: 46.3 million Americans age 12+ had substance use disorder 2021 (16.5% population). Breakdown: Alcohol 29.5 million, cannabis 16.3 million, opioids 5.6 million (2.7M prescription opioids, 1.1M heroin, 1.8M fentanyl), cocaine 1.4 million, methamphetamine 2.5 million. Polysubstance use common (40% use multiple drugs). Age: Highest 18-25 (16%), decreasing with age. Socioeconomic: All levels but higher rates lower income, unemployed, incarcerated, homeless.

Overdose Deaths - Epidemic: 107,622 deaths 2021 (294/day, 1 every 5 minutes). Trend: 16,849 deaths 1999 → 70,630 in 2019 → 107,622 in 2021 (5-fold increase, COVID accelerated). Opioids 80,411 (75%): Synthetic opioids (mostly fentanyl) 71,238, heroin 9,173, prescription opioids 16,416 (overlap - polysubstance). Stimulants: Psychostimulants with abuse potential (meth) 32,537, cocaine 24,486. Often combined: Fentanyl contaminating cocaine/meth (60% of stimulant deaths involve opioids). Age-adjusted rate: 32.4 per 100,000 (vs. 6.1 in 1999). Geographic: Highest Appalachia, Rust Belt, Southwest. Racial: Highest American Indian/Alaska Native (41.4 per 100,000), Black (38.2), White (36.8).

Economic Impact: $600+ billion annually (NIDA estimate): Healthcare $89B, criminal justice $61B, lost productivity $464B. Per capita: $10,000+ lifetime excess costs per person with SUD. Specific: Opioid epidemic alone $631B in 2019 (fentanyl crisis worsened since). Lost work: 25+ working-age deaths/100,000 population.

Current Treatment Landscape - Major Gaps

Opioid Use Disorder (OUD): Gold standard - Medication-Assisted Treatment (MAT): (1) Methadone - full mu-opioid agonist, prevents withdrawal + blocks heroin, daily clinic dosing, 40-50% retention 1 year, reduces mortality 50%; (2) Buprenorphine (Suboxone) - partial agonist, less euphoria, withdrawal suppression, office-based, 30-40% retention; (3) Naltrexone (Vivitrol) - antagonist, blocks all opioids, requires 7-10 days detox first (difficult), monthly injection, 30% retention. Problem: Only 20% OUD patients receive MAT (access barriers - lack of providers, insurance, stigma). High relapse: 40-60% within 1 year even on MAT. Overdose risk spike post-treatment (tolerance lost). Need better retention, relapse prevention.

Stimulant Use Disorders (Cocaine, Meth): NO FDA-approved medications. Behavioral therapies only: Contingency management (financial incentives for negative urine tests, 20-30% abstinence but funding issues), cognitive-behavioral therapy (CBT, 20% success), community reinforcement approach. Experimental medications: Meth - naltrexone + bupropion combo (13% vs. 3% placebo, modest); Cocaine - no effective medication despite 30+ years trials (dopamine agonists, disulfiram, topiramate all failed). HUGE unmet need - 50,000+ stimulant deaths with no pharmacotherapy.

Behavioral Interventions: Necessary but insufficient. Inpatient rehab (30-90 days) - expensive ($5,000-$40,000), 40-60% relapse within year. Outpatient counseling - 20-30% sustained abstinence. 12-step programs (AA, NA) - free, peer support, 20-30% long-term success. Therapeutic communities - long-term residential, higher success (50%) but limited capacity. All more effective when combined with medications (for OUD) but stimulants lack pharmacotherapy.

Addiction Vaccines - Unique Value Proposition

Advantages: Pharmacological option for stimulants (currently none). Relapse prevention - if vaccinated person uses, no euphoria → reduced reinforcement. Overdose protection - particularly fentanyl vaccine (sequester lethal doses). Long-acting - boosters quarterly-yearly vs. daily pills (better compliance). No abuse potential. Preserves cognition (unlike some medications affecting neurotransmitters broadly). Adjunct to MAT - vaccine + buprenorphine for opioids synergistic. Harm reduction tool - vaccinate without requiring abstinence commitment.

Challenges: Same as nicotine vaccines: Individual variability (30-60% responders), high drug doses overwhelming antibodies (cocaine binges, fentanyl potency), time lag (weeks for antibodies), polydrug use (cocaine vaccine doesn't block alcohol, opioids). Societal: Stigma ("Why vaccinate addicts?"), insurance coverage uncertain, criminal justice implications (mandatory vaccination?), ethical concerns (autonomy, informed consent). Commercial: Expensive development, patient population poor/uninsured/incarcerated (limited revenue potential), prior failures (TA-CD Phase 2 modest results) reducing investor enthusiasm. Regulatory: Addiction endpoints subjective (urine tests falsifiable, self-report unreliable), high placebo response, need large trials.

Realistic Role: Not standalone cure, not first-line. Positioned as: Adjunct to MAT (vaccine + methadone/buprenorphine for OUD), relapse prevention during high-risk periods (post-detox, criminal justice re-entry), stimulant use disorders (where no medications exist - vaccine may be only pharmacotherapy), motivated patients (vaccine requires commitment - multiple injections, behavioral therapy), harm reduction (overdose prevention with fentanyl vaccine, reducing risky use). Success metric: If cocaine vaccine improves 1-year abstinence from 20% to 30% in combination therapy - 50% relative improvement would help 10,000+ Americans yearly. Fentanyl vaccine preventing even 10% of overdoses = 7,000 lives saved annually.

Future of Addiction Treatment 2025-2045

Near-Term (2025-2030): TA-CD or next-gen cocaine vaccine approval for cocaine use disorder + behavioral therapy. Fentanyl vaccine approval as harm reduction (vaccinate high-risk populations - OUD patients, recently incarcerated, communities with fentanyl-contaminated supply). Heroin vaccine Phase 3 trials with buprenorphine combination. Methamphetamine vaccine + naltrexone/bupropion combo. Improved MAT delivery (monthly buprenorphine implants/injections, telemedicine expansion). Overdose prevention: Widespread naloxone access, fentanyl test strips, supervised consumption sites.

Mid-Term (2030-2040): dAd5GNE or mRNA addiction vaccines (single injection, sustained antibodies years, no compliance issues). Multi-drug vaccines (cocaine + meth, heroin + fentanyl in one formulation). Monoclonal antibodies for acute overdose (replace naloxone - longer duration, no re-narcotization risk). Precision addiction medicine: Genetic testing → personalized treatment (vaccine if high immune responder, specific medications based on pharmacogenomics, CYP2D6 variants). Psychedelic-assisted therapy (psilocybin, MDMA for addiction - Phase 3 trials showing promise). Brain stimulation (TMS, DBS for severe refractory addiction). Microbiome therapies (gut-brain axis). Digital therapeutics (app-based CBT, AI coaching, wearable sensors detecting relapse risk).

Long-Term Vision (2040+): Overdose deaths reduced 50% (107K → 53K through vaccines, improved MAT, harm reduction). Fentanyl crisis ended (vaccines + supply interdiction + safer prescribing). Stimulant deaths reduced 70% (effective pharmacotherapy available - vaccines + medications). OUD treatment coverage 80% (vs. current 20% - access barriers eliminated). Criminal justice reform - treatment not incarceration (Portugal model - decriminalization + mandatory treatment). Preventive vaccination - high-risk youth (family history, adverse childhood experiences) vaccinated prophylactically. Stigma reduction - addiction recognized as brain disease not moral failure. Comprehensive approach: Vaccines + MAT + behavioral therapy + social support + housing + employment → 50-60% long-term recovery rates (vs. current 20-30%). Vision: Addiction becomes manageable chronic disease like diabetes - pharmacotherapy controls symptoms, relapses treated not criminalized, quality of life restored, full societal integration.